tiprankstipranks
Trending News
More News >
Circassia Pharmaceuticals (GB:NIOX)
:NIOX

Circassia Pharmaceuticals (NIOX) AI Stock Analysis

Compare
13 Followers

Top Page

GB

Circassia Pharmaceuticals

(LSE:NIOX)

Rating:69Neutral
Price Target:
71.00p
â–˛(2.90%Upside)
Circassia Pharmaceuticals scores well on financial performance due to strong revenue growth and cash flow management. Technical analysis and valuation indicate some caution with potential overvaluation. Corporate events suggest strategic growth but also highlight risks from the economic environment. Overall, the stock presents a balanced investment profile with both strengths and concerns.
Positive Factors
Acquisition Interest
NIOX has announced it has received a possible 81p/share all-cash offer from Keensight Capital valuing the business at ÂŁ322m.
Financial Performance
NIOX's fiscal year trading update confirms another solid period of growth, with revenues increasing by 14% to ÂŁ41.8 million, in line with consensus expectations.
Operational Efficiency
Stronger-than-expected operational leverage saw adjusted EBITDA grow by 21% to ÂŁ13.8 million, exceeding consensus estimates.
Negative Factors
Macroeconomic Concerns
Keensight Capital has announced that it does not intend to make a firm offer for the business at this stage due to the current uncertain macroeconomic environment.
Share Price Volatility
A level of weakness in the share price is anticipated due to recent newsflow and share price action related to it.

Circassia Pharmaceuticals (NIOX) vs. iShares MSCI United Kingdom ETF (EWC)

Circassia Pharmaceuticals Business Overview & Revenue Model

Company DescriptionNIOX Group Plc engages in the design, development, and commercialization of medical devices for the measurement of fractional exhaled nitric oxide (FeNo) worldwide. Its products include NIOX VERO, a non-invasive and point-of-care system that comprises a small portable device and a range of consumables, including sensors, individual disposable mouthpieces, and breathing handles for the measurement of FeNo level in patients. The company was formerly known as Circassia Group Plc and changed its name to NIOX Group Plc in September 2022. NIOX Group Plc was incorporated in 2006 and is headquartered in Oxford, the United Kingdom.
How the Company Makes MoneyCircassia Pharmaceuticals generates revenue through the sale and distribution of its NIOX VERO devices and associated consumables, such as test kits and sensors, to healthcare providers and institutions globally. The company's revenue model is primarily based on a combination of direct sales and distribution partnerships in various regions, allowing them to reach a broad customer base. Significant partnerships with medical institutions and healthcare organizations enhance its market presence and expand its sales channels. Additionally, Circassia may engage in licensing agreements and collaboration with other pharmaceutical and biotech companies to further leverage its technology and expertise, contributing to its revenue streams.

Circassia Pharmaceuticals Financial Statement Overview

Summary
Income Statement
Balance Sheet
Cash Flow
Breakdown
TTMDec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Income StatementTotal Revenue
48.00M36.80M31.30M27.90M23.90M34.60M
Gross Profit
34.40M26.50M22.20M19.00M16.30M25.50M
EBIT
6.60M4.60M1.80M-4.30M-17.30M-18.50M
EBITDA
11.20M8.70M15.40M3.10M-9.10M-12.10M
Net Income Common Stockholders
14.30M10.70M16.10M3.60M-33.50M-16.80M
Balance SheetCash, Cash Equivalents and Short-Term Investments
19.90M19.90M19.40M12.60M7.40M27.00M
Total Assets
91.50M91.50M98.50M86.40M103.10M246.80M
Total Debt
1.10M1.10M1.00M1.30M1.60M111.40M
Net Debt
-18.80M-18.80M-18.40M-11.30M-5.80M84.40M
Total Liabilities
7.70M7.70M16.60M19.60M37.00M162.00M
Stockholders Equity
83.80M83.80M81.90M66.80M66.10M84.80M
Cash FlowFree Cash Flow
15.70M11.30M6.60M1.20M-24.40M-25.40M
Operating Cash Flow
15.80M11.60M6.70M1.40M-23.90M-25.10M
Investing Cash Flow
-600.00K-300.00K-100.00K-200.00K-500.00K-9.90M
Financing Cash Flow
-19.50M-10.50M-500.00K4.10M4.30M21.90M

Circassia Pharmaceuticals Technical Analysis

Technical Analysis Sentiment
Positive
Last Price69.00
Price Trends
50DMA
66.16
Positive
100DMA
63.82
Positive
200DMA
63.59
Positive
Market Momentum
MACD
1.44
Negative
RSI
55.62
Neutral
STOCH
77.82
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:NIOX, the sentiment is Positive. The current price of 69 is above the 20-day moving average (MA) of 67.18, above the 50-day MA of 66.16, and above the 200-day MA of 63.59, indicating a bullish trend. The MACD of 1.44 indicates Negative momentum. The RSI at 55.62 is Neutral, neither overbought nor oversold. The STOCH value of 77.82 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:NIOX.

Circassia Pharmaceuticals Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
69
Neutral
ÂŁ288.02M78.414.55%1.81%13.59%-66.27%
65
Neutral
£333.86M8.4911.74%―38.80%―
GBAPH
59
Neutral
$355.92M―-5.04%―-1.02%67.70%
54
Neutral
$5.31B3.29-45.39%2.79%16.77%-0.07%
GBAGY
51
Neutral
£324.12M―-369.20%―4.50%74.32%
£125.57M―-73.02%―――
$496.59M―-66.23%―――
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
GB:NIOX
Circassia Pharmaceuticals
69.00
1.04
1.53%
GB:AGY
Allergy Therapeutics
6.80
0.80
13.33%
GB:APH
Alliance Pharma
64.70
29.35
83.03%
GB:AVCT
Avacta Group plc
32.50
-8.00
-19.75%
GB:PRTC
PureTech Health
139.00
-85.00
-37.95%
OXBDF
Oxford BioMedica
4.77
0.52
12.24%

Circassia Pharmaceuticals Corporate Events

Regulatory Filings and Compliance
NIOX Group Updates Total Voting Rights Following Share Option Exercises
Neutral
Jun 2, 2025

NIOX Group plc, a company listed on AIM, has announced an update regarding its total voting rights. As of May 31, 2025, the company has 417,417,579 Ordinary Shares in issue, each carrying one voting right, with no shares held in treasury. Recent exercises of employee share options have resulted in the issuance of 735,050 new Ordinary Shares, which have been admitted via block listing and rank equally with existing shares. This update is relevant for shareholders calculating their interest in the company under FCA’s rules.

The most recent analyst rating on (GB:NIOX) stock is a Buy with a £77.00 price target. To see the full list of analyst forecasts on Circassia Pharmaceuticals stock, see the GB:NIOX Stock Forecast page.

Regulatory Filings and Compliance
Niox Group PLC Announces Change in Voting Rights
Neutral
May 28, 2025

Niox Group PLC, a UK-based company, has undergone a change in its voting rights structure due to an acquisition or disposal by Danske Bank A/S, a financial institution based in Copenhagen, Denmark. The notification indicates that Danske Bank’s voting rights in Niox Group have decreased from 3.43072% to 2.99176%, as of May 23, 2025. This change reflects a shift in the company’s shareholder dynamics, potentially impacting its governance and decision-making processes.

The most recent analyst rating on (GB:NIOX) stock is a Buy with a £77.00 price target. To see the full list of analyst forecasts on Circassia Pharmaceuticals stock, see the GB:NIOX Stock Forecast page.

Business Operations and Strategy
NIOX Group PLC Appoints New Sole Broker
Neutral
May 27, 2025

NIOX Group PLC has announced a change in its advisory team, with Singer Capital Markets now serving as the sole broker and continuing as the company’s Nominated Adviser. This strategic move is expected to streamline NIOX’s financial advisory services, potentially enhancing its market operations and positioning within the pharmaceutical industry.

The most recent analyst rating on (GB:NIOX) stock is a Buy with a £77.00 price target. To see the full list of analyst forecasts on Circassia Pharmaceuticals stock, see the GB:NIOX Stock Forecast page.

Other
Niox Group PLC Announces Change in Voting Rights
Neutral
May 23, 2025

Niox Group PLC, a UK-based company, has experienced a change in the breakdown of its voting rights, as reported by Harwood Capital LLP. The notification indicates that Harwood Capital LLP’s voting rights in Niox Group have decreased from 17.8802% to 16.876%, reflecting a shift in shareholder influence.

The most recent analyst rating on (GB:NIOX) stock is a Buy with a £77.00 price target. To see the full list of analyst forecasts on Circassia Pharmaceuticals stock, see the GB:NIOX Stock Forecast page.

Delistings and Listing Changes
NIOX Group Announces Block Listing of Shares on AIM
Neutral
May 21, 2025

NIOX Group plc, a company involved in the healthcare sector, has announced a block listing application for 1,207,893 ordinary shares to be admitted to trading on AIM. This move is associated with the exercise of options under the company’s Performance Share Plan Scheme 2019 and Save As You Earn Plan 2022. The admission of these shares is expected to take effect on 28 May 2025, and they will rank equally with existing shares, potentially impacting the company’s market presence and shareholder value.

The most recent analyst rating on (GB:NIOX) stock is a Buy with a £77.00 price target. To see the full list of analyst forecasts on Circassia Pharmaceuticals stock, see the GB:NIOX Stock Forecast page.

Business Operations and StrategyRegulatory Filings and Compliance
Niox Group PLC Sees Major Shift in Shareholder Voting Rights
Neutral
May 21, 2025

Niox Group PLC, a UK-based company, has experienced a significant change in its shareholder structure. Rathbones Investment Management Ltd and Investec Wealth & Investment Limited have increased their voting rights in Niox Group PLC to 10.7058%, up from the previous 5.2724%. This acquisition of voting rights indicates a strategic move by these investment firms, potentially impacting the company’s governance and decision-making processes.

The most recent analyst rating on (GB:NIOX) stock is a Buy with a £77.00 price target. To see the full list of analyst forecasts on Circassia Pharmaceuticals stock, see the GB:NIOX Stock Forecast page.

Business Operations and StrategyRegulatory Filings and Compliance
Niox Group PLC Announces Change in Major Holdings
Neutral
May 21, 2025

Niox Group PLC, a company involved in the pharmaceutical industry, has announced a change in its major holdings. Richard Griffiths and his controlled holdings have adjusted their voting rights in Niox Group PLC, resulting in a decrease from 8.91% to 5.96%. This change is attributed to the dilution on the issue of options and reflects a shift in the company’s shareholder structure, potentially impacting its governance and strategic decision-making.

The most recent analyst rating on (GB:NIOX) stock is a Buy with a £77.00 price target. To see the full list of analyst forecasts on Circassia Pharmaceuticals stock, see the GB:NIOX Stock Forecast page.

Other
NIOX Group Directors Exercise Share Options and Adjust Shareholdings
Neutral
May 21, 2025

NIOX Group plc, a company listed on the AIM market, announced that its directors, Ian Johnson and Jonathan Emms, exercised share options awarded under the company’s Performance Share Plan. This exercise resulted in the issuance of 6,272,099 new ordinary shares and the transfer of 6,000,000 shares from treasury. To cover tax liabilities and other costs, the directors sold 6,670,555 shares at 65.0 pence each. The company’s issued share capital now consists of 416,682,529 ordinary shares, each carrying one voting right, with no shares held in treasury.

The most recent analyst rating on (GB:NIOX) stock is a Buy with a £77.00 price target. To see the full list of analyst forecasts on Circassia Pharmaceuticals stock, see the GB:NIOX Stock Forecast page.

Product-Related AnnouncementsExecutive/Board ChangesBusiness Operations and StrategyFinancial Disclosures
NIOX Group Reports Strong Start to 2025 and Outlines Strategic Priorities
Positive
May 14, 2025

NIOX Group plc reported a strong start to 2025 with a 21% increase in sales, driven by significant growth in its research business due to increased clinical trial activity. The company is prioritizing the expansion of FeNO testing in the US, the launch of the NIOX PRO® device, and the development of a home-use device. Despite a one-off cost from a withdrawn bid and upcoming board changes, NIOX remains optimistic about its financial health and strategic direction.

The most recent analyst rating on (GB:NIOX) stock is a Buy with a £77.00 price target. To see the full list of analyst forecasts on Circassia Pharmaceuticals stock, see the GB:NIOX Stock Forecast page.

Shareholder MeetingsDividends
NIOX Group Announces Final Dividend Timetable for 2024
Neutral
Apr 24, 2025

NIOX Group plc, a company listed on the AIM market, has announced a timetable for its proposed final dividend for the financial year ending 31 December 2024. The dividend of 1.25 pence per share is subject to approval at the Annual General Meeting on 14 May 2025, with key dates including an ex-dividend date of 15 May 2025 and a payment date of 16 June 2025.

Shareholder Meetings
NIOX Group Announces 2025 AGM Details
Neutral
Apr 15, 2025

NIOX Group plc, a company listed on the AIM market, has announced the publication of its Notice of the 2025 Annual General Meeting on its website. The meeting is scheduled for May 14, 2025, at their registered office in Oxford, England, and shareholders have been sent copies of the 2024 Annual Report and Accounts if requested.

Regulatory Filings and Compliance
Niox Group PLC Announces Change in Voting Rights
Neutral
Apr 14, 2025

Niox Group PLC, a UK-based company, has announced a change in the breakdown of its voting rights due to an acquisition or disposal of financial instruments. Spreadex LTD, a regulated provider of spread betting and CFD trading, has adjusted its position in Niox Group, resulting in a decrease in its voting rights from 3.0694% to 2.4063%. This adjustment reflects a shift in the financial instruments held by Spreadex, impacting the overall voting influence within Niox Group.

Regulatory Filings and Compliance
NIOX Group’s Director-Related Share Transaction Announced
Neutral
Apr 11, 2025

NIOX Group plc, a company listed on the AIM market, announced a transaction involving Áinne Naylor, a Person Closely Associated with Robert Naylor, a Non-Executive Director. Áinne Naylor purchased 44,166 Ordinary Shares at £0.565 per share, increasing Robert Naylor’s total shareholding to 44,166 shares, representing 0.01% of the company’s voting rights. This transaction is part of the company’s ongoing compliance with UK MAR regulations, ensuring transparency in managerial transactions.

Private Placements and FinancingBusiness Operations and StrategyFinancial Disclosures
NIOX Group Discontinues Private Sale Amid Economic Challenges
Negative
Apr 11, 2025

NIOX Group PLC, a company in the pharmaceutical industry, has announced that Keensight Capital will not make a firm offer for the company due to current macroeconomic conditions. Consequently, NIOX has decided to discontinue its Private Sale Process, as it is unlikely to achieve optimal outcomes for shareholders. Despite these developments, NIOX reported an 18% sales growth in the first quarter of the year and a net cash position of £15.4 million as of March 31, 2025.

Delistings and Listing Changes
NIOX Group Seeks Block Admission for Share Trading on AIM
Neutral
Apr 10, 2025

NIOX Group plc, a company involved in the healthcare sector, has applied for a block admission of 6,862,848 ordinary shares to be traded on AIM at the London Stock Exchange. This move is part of the company’s 2022 Performance Share Plan Scheme, and the shares are expected to be admitted by 16 April 2025, aligning with existing shares and potentially impacting the company’s market presence.

Executive/Board ChangesPrivate Placements and Financing
NIOX Group Issues New Shares to Executive Directors
Neutral
Apr 1, 2025

NIOX Group plc, a company listed on the AIM market, has issued 363,006 new ordinary shares to its Executive Directors as part of its Deferred Share Bonus Plan. This issuance, related to the 2022 financial year’s annual bonus, follows the release of the company’s year-end results and marks the end of its closed period. The new shares are part of an existing block admission and align with the company’s remuneration policy, which defers a portion of bonuses for two years. This move reflects NIOX’s commitment to aligning executive incentives with shareholder interests, potentially impacting the company’s stock liquidity and executive shareholding structure.

M&A TransactionsBusiness Operations and StrategyFinancial Disclosures
NIOX Group Reports Strong Financial Growth and Strategic Developments for 2024
Positive
Apr 1, 2025

NIOX Group PLC reported a 14% revenue growth to £41.8 million for the year ended 31 December 2024, with a 21% increase in adjusted EBITDA to £13.8 million. The company announced a proposal from Keensight Capital for a potential acquisition, though discussions are preliminary. Operationally, NIOX saw a 19% increase in NIOX® FeNO tests sold and is on track to launch the NIOX PRO® device in Q4 2025. The company is expanding its manufacturing capacity and distributor network, with plans to return 80% of free cash flow to shareholders, reflecting strong financial health and strategic growth initiatives.

Business Operations and StrategyRegulatory Filings and Compliance
Niox Group PLC Sees Increase in Voting Rights by Spreadex LTD
Neutral
Mar 26, 2025

Niox Group PLC, a UK-based company, has announced a change in its financial instrument holdings, with Spreadex LTD increasing its voting rights through financial instruments to 3.0694%. This adjustment reflects a rise from the previous 2.238264% and indicates a strategic positioning by Spreadex LTD, a regulated provider of spread betting and CFD trading, to potentially influence Niox Group’s decision-making processes. This development may impact stakeholders as it suggests a shift in the control dynamics within the company.

Other
Niox Group PLC Announces Change in Voting Rights
Neutral
Mar 25, 2025

Niox Group PLC, a UK-based company, has announced a change in the voting rights held by Danske Bank A/S. The bank, headquartered in Copenhagen, Denmark, has reduced its voting rights in Niox Group from 4.059295% to 3.43072%, as of March 24, 2025. This change reflects a disposal of voting rights, potentially impacting the company’s shareholder dynamics and market perception.

M&A Transactions
NIOX Group Plc Considers Acquisition Proposal from Keensight Capital
Neutral
Mar 20, 2025

NIOX Group Plc has received a revised proposal from Keensight Capital for a potential cash offer to acquire the company at 81 pence per share. The board is considering the offer and has allowed Keensight to conduct due diligence, though discussions are still in the preliminary stages. The company is also exploring other potential offers to maximize shareholder value.

M&A Transactions
NIOX Group Receives Revised Acquisition Proposal from Keensight Capital
Neutral
Mar 20, 2025

NIOX Group Plc has received a revised proposal from Keensight Capital for a potential cash offer to acquire the company at 81 pence per share, following a previous offer of 78 pence per share. The board is considering the proposal, which is subject to due diligence, and has also initiated a private sale process to explore other potential offers, though no firm offers have been made yet.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.